Showing results (221-230 of 1,075) with videos related to

Sort By:
Pageof 108
Circulation. Cardiovascular Quality and Outcomes|January 16, 2014
Using internally developed risk models to assess heterogeneity in treatment effects in clinical trialsJames F Burke, Rodney A Hayward, Jason P Nelson, et al.
Structural Heart : the Journal of the Heart Team|September 9, 2020
Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? A Systematic ReviewBenjamin S Wessler, Andrew R Weintraub, James E Udelson, et al.
The Biochemical Journal|November 15, 1989
Site-directed mutagenesis of the Klebsiella pneumoniae nitrogenase. Effects of modifying conserved cysteine residues in the alpha- and beta-subunitsH M Kent, I Ioannidis, C Gormal, et al.
Molecular Microbiology|August 5, 2017
Analysis of site-directed mutations in the α-and β-subunits of Klebsiella pneumoniae nitrogenaseH M Kent, M Baines, C Gormal, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 31, 2017
Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life ExpectancyDavid van Klaveren, John B Wong, David M Kent, et al.
BMJ Open Quality|June 30, 2026
Australian and New Zealand nurses' understanding and application of aseptic technique in clinical contexts: a cross-sectional mixed-method studyHannah M Kent, Joanne M Lewis, Sonja A Dawson, et al.
Journal of Molecular Biology|March 7, 1997
Molecular interactions between the importin alpha/beta heterodimer and proteins involved in vertebrate nuclear protein importP Percipalle, W D Clarkson, H M Kent, et al.
Journal of Clinical Epidemiology|November 15, 2017
The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effectsDavid van Klaveren, Ewout W Steyerberg, Patrick W Serruys, et al.
The American Journal of Medicine|December 29, 2017
Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk ModelJenica N Upshaw, David van Klaveren, Marvin A Konstam, et al.
Chemical Research in Toxicology|December 17, 2002
Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoproteinAnna L Blobaum, Ute M Kent, William L Alworth, et al.
Pageof 108